Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2

Not yet recruiting

• Conditions: Gastric Cancer; HER2 + Gastric Cancer; PD-L1 Positive; CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
• Interventions: Drug: Trastuzumab; Drug: Capecitabine; Drug: Apatinib; Drug: Adebrelimab; Drug: SHR-A1811; Drug: Oxaliplatin; Drug: S-1; Drug: SHR-A1904; Drug: SHR-1701; Drug: zolbetuximab

• Registration Number: NCT06881017
• Lead Sponsor: China Medical University, China

Brief Summary

This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling (HER2, CLDN18.2, and PD-L1) via next-generation sequencing (NGS) or immunohistochemistry (IHC). Participants will be stratified into distinct molecular subtypes and assigned subtype-specific therapeutic regimens. The primary objectives are to assess treatment efficacy (e.g., objective response rate) and safety profiles across molecularly defined cohorts.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-09
• Study First Submitted QC: 2025-03-17
• Last Update Submitted: 2025-03-17
• Study First Posted: 2025-03-18
• Last Update Posted: 2025-03-18
• Study Start: 2025-05-01
• Primary Completion: 2029-08-01
• Study Completion: 2029-11-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Age ≥18 years, regardless of gender;

2. Histologically or pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction;

3. Advanced or metastatic disease with no prior systemic therapy for advanced-stage disease (Patients who relapsed >6 months after completing neoadjuvant/adjuvant therapy are eligible, with prior neoadjuvant/adjuvant regimens not counted as prior lines of therapy);

4. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1);

5. Archival or fresh tumor tissue sample available for biomarker testing (HER2, CLDN18.2, and PD-L1 expression);

6. ECOG performance status: 0-1;

7. Life expectancy ≥12 weeks;

8. Adequate organ and bone marrow function meeting the following criteria:

   1. Hemoglobin ≥90 g/L (no blood transfusion within 14 days);
   2. Absolute neutrophil count (ANC) ≥1.5×10⁹/L;
   3. Platelet count ≥90×10⁹/L;
   4. Total bilirubin ≤1.5×upper limit of normal (ULN);
   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN if liver metastases are present);
   6. Serum creatinine ≤1.5×ULN;
   7. Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; QTc interval <450 ms for males and <470 ms for females;

9. Coagulation parameters:

10. For patients not on anticoagulation therapy: INR ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN;

11. For patients receiving full-dose or parenteral anticoagulation: Stable anticoagulant dose for ≥2 weeks prior to enrollment, with coagulation tests within the therapeutic range;

12. Contraception requirements:

13. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and agree to use effective contraception during the study and for 3 months after the last dose;

14. Men must be surgically sterile or agree to use effective contraception during the study and for 3 months after the last dose;

15. Recovery from prior therapy-related toxicities to ≤Grade 1 (surgical wounds must be fully healed if applicable);

16. Voluntary participation with signed informed consent form and anticipated adherence to protocol requirements.

Exclusion Criteria

1. History of gastrointestinal perforation and/or fistula within 6 months prior to treatment, or active gastrointestinal bleeding within 3 months;

2. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage;

3. Known history of hypersensitivity to any component of the investigational drug(s) or excipients;

4. Prior treatments meeting any of the following:

   1. Received any investigational drug within 4 weeks prior to the first dose of the study drug or within 5 half-lives of the last investigational agent (whichever is shorter);
   2. Concurrent enrollment in another interventional clinical study (observational or follow-up studies are permitted);
   3. Received antitumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologics, or tumor embolization) within 2 weeks prior to the first dose of the study drug;

5. History of leptomeningeal metastasis or current active brain metastases;

6. Severe infection (CTCAE v5.0 Grade >2) within 4 weeks prior to the first dose of the study drug (e.g., pneumonia requiring hospitalization, bacteremia, or septic complications); active pulmonary inflammation on baseline chest imaging, or signs/symptoms of infection requiring oral/IV antibiotics within 2 weeks prior to the first dose (prophylactic antibiotics excluded);

7. History of interstitial lung disease (except radiation pneumonitis without steroid treatment or non-infectious pneumonitis);

8. Active tuberculosis (TB) infection confirmed by medical history or CT scan, history of active TB within 1 year prior to enrollment, or untreated active TB diagnosed >1 year prior to enrollment;

9. Diagnosis of another malignancy within 5 years prior to the first dose of the study drug, except malignancies with low metastatic/lethal risk (5-year survival rate >90%), such as adequately treated basal cell carcinoma, squamous cell skin cancer, or carcinoma in situ of the cervix;

10. Pregnant or lactating women;

11. Other conditions deemed by the investigator to jeopardize subject safety or trial integrity, including severe comorbidities (e.g., psychiatric disorders), clinically significant laboratory abnormalities, or social/family factors that may compromise protocol adherence or data collection.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	Trastuzumab	HER2(+)\&CLDN18.2(+)\&PD-L1(+)
Cohort 1	Adebrelimab	HER2(+)\&CLDN18.2(+)\&PD-L1(+)
Cohort 2	Trastuzumab	HER2(+)\&CLDN18.2(+)\&PD-L1(-)
Cohort 1	S-1	HER2(+)\&CLDN18.2(+)\&PD-L1(+)
Cohort 1	zolbetuximab	HER2(+)\&CLDN18.2(+)\&PD-L1(+)
Cohort 2	SHR-A1904	HER2(+)\&CLDN18.2(+)\&PD-L1(-)
Cohort 3	S-1	HER2(2+ or 3+)\&CLDN18.2(-)\&PD-L1(-)
Cohort 1	SHR-A1904	HER2(+)\&CLDN18.2(+)\&PD-L1(+)
Cohort 2	S-1	HER2(+)\&CLDN18.2(+)\&PD-L1(-)
Cohort 3	SHR-A1811	HER2(2+ or 3+)\&CLDN18.2(-)\&PD-L1(-)
Cohort 4	Adebrelimab	HER2(-)\&CLDN18.2(+)\&PD-L1(+)
Cohort 4	S-1	HER2(-)\&CLDN18.2(+)\&PD-L1(+)
Cohort 4	SHR-A1904	HER2(-)\&CLDN18.2(+)\&PD-L1(+)
Cohort 5	Capecitabine	HER2(-)\&CLDN18.2(-)\&PD-L1(+)
Cohort 5	Oxaliplatin	HER2(-)\&CLDN18.2(-)\&PD-L1(+)
Cohort 5	SHR-1701	HER2(-)\&CLDN18.2(-)\&PD-L1(+)
Cohort 6	S-1	HER2(-)\&CLDN18.2(+)\&PD-L1(-)
Cohort 6	SHR-A1904	HER2(-)\&CLDN18.2(+)\&PD-L1(-)
Cohort 7	Apatinib	HER2(-)\&CLDN18.2(-)\&PD-L1(-)
Cohort 7	S-1	HER2(-)\&CLDN18.2(-)\&PD-L1(-)
Cohort 7	Oxaliplatin	HER2(-)\&CLDN18.2(-)\&PD-L1(-)

Primary Outcome Measures

Name	Time	Method
ORR	2year	Objective Response Rate (ORR) is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) to a therapeutic intervention, as assessed by standardized criteria (e.g., RECIST 1.1 for solid tumors). It serves as a key efficacy endpoint in early-phase clinical trials to evaluate the preliminary antitumor activity of investigational therapies.

Secondary Outcome Measures

Name	Time	Method
OS	2year	Overall Survival (OS) is defined as the time from randomization (or initiation of treatment) until death from any cause. It is considered the gold standard endpoint in oncology clinical trials due to its objectivity and direct relevance to patient benefit.